In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1, 3galactosyltransferase gene

Cancer Gene Therapy

Volumn 12, Issue 6, 2005, Pages 528-539

  Deriy, Lucy ^a   Ogawa, Haruko ^b   Gao, Guang Ping ^c   Galili, Uri ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

gal epitope; 1, 3galactosyltransferase; Adenovirus transduction; Anti Gal; APC targeting; Autologous tumor vaccine

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; EPITOPE; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; TUMOR VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL DIVISION; CELL PROTECTION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; GRAFT REJECTION; IMMUNOGENICITY; IN VIVO STUDY; LYMPH NODE; MALE; MELANOMA; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR CELL; VACCINATION; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; ERYTHROCYTES; FEMALE; GALACTOSYLTRANSFERASES; GENE THERAPY; IMMUNODOMINANT EPITOPES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 18844431826     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700812     Document Type: Article

References (69)

1. Lucas S, De Plaen E, Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer. 2000;87:55-60.
2. Pardoll DM. Cancer vaccines. Immunol Today. 1993;14:310-316.
3. Old LJ. Immunotherapy for cancer. Sci Am. 1996;275:136-143.
4. Livingston P. Active specific immunotherapy in the treatment of patients with cancer. Immunol Allerg Clin N Am. 1991;11:401-423.
5. Berd D, Maguire Jr HC, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 1997;15:2359-2370.
6. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother. 2002;51:45-55.
7. Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161:777-782.
8. Zitvogel L, Mayordoma JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183:87-97.
9. Maass G, Schmidt W, Berger M, et al. Primary of tumor-specific T cells in the draining lymph nodes after immunization with interleukin-2 secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA. 1995;92:5540-5544.
10. Grabbe S, Beisserts S, Schwartz T, Granstein RD. Dendritic cells as initiators of tumor immune response: A possible strategy for tumor immunotherapy. Immunol Today. 1995;16:117-121.
11. Zinkernagel RM, Ehl E, Aichele P, Kündig T, Hengartner H. Antigen localization regulates immune responses in a dose and time dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997;156:199-209.
12. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
13. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005.
14. Unkeless JC. Functional heterogeneity of human Fc receptors for immunoglobulin G. J Clin Invest. 1989;83:355-361.
15. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and Type II (CD32) Fc receptor-mediated phagocytosis by human blood dendritic cells. J Immunol. 1996;157:541-548.
16. Schmitt DA, Hanan D, Bieber T, et al. Human epidermal Langerhans cells express only the 40-kilodalton Fcγ receptor (FcRII). J Immunol. 1990;144:4284-4290.
17. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest. 2002;110:71-79.
18. Regnault A, Lankar D, Lacabanne V, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189:371-380.
19. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol. 2002;168:2240-2246.
20. Stoner RD, Terres G. Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody. J Immunol. 1963;91:761-770.
21. Manca F, Fenoglio D, LiPira G, Kunkl A, Celada F. Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med. 1991;173:37-48.
22. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre P. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J Immunol. 1992;149:3477-3781.
23. Celis E, Chang TW. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science. 1984;224:297-299.
24. Celis E, Abraham KG, Miller RW. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology. 1987;7:563-568.
25. Villinger F, Mayne AE, Bostik P, et al. Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol. 2003;77:10-24.
26. Stager S, Alexander J, Kirby AC, et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8(+) T-cell responses. Nat Med. 2003;9:1287-1292.
27. Galili U, LaTemple DC. The natural anti-Gal antibody as a universal augmenter of autologous vaccine immunogenicity. Immunol Today. 1997;18:281-285.
28. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of α-galactosyl epitopes by recombinant α1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res. 1996;56:3069-3074.
29. Galili U. Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother. 2004;53:935-945.
30. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med. 1984;160:1519-1531.
31. Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1-3)-linked galactose residues. J Exp Med. 1985;162:573-582.
32. Galili U, Buehler J, Shohet SB, Macher BA. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J Exp Med. 1987;165:693-704.
33. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc Natl Acad Sci USA. 1987;84:1369-1373.
34. Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem. 1988;263:17755-17762.
35. Galili U, Swanson K. Gene sequences suggest inactivation of α1,3galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA. 1991;88:7401-7404.
36. Joziasse DH, Shaper JH, Van den Eijnden DH, Van Tunen AH, Shaper NL. Bovine α1-3galactosyltransferase: isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA. J Biol Chem. 1989;264:14290-14297.
37. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Galβ-D-Gal(1,4)-D-GlcNAcα(1,3) galactosyltransferase cDNA. J Biol Chem. 1990;265:7055-7062.
38. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today. 1993;14:480-482.
39. Good H, Cooper DKC, Malcolm AJK, et al. Identification of carbohydrate structures which bind human anti-porcine Abs: implications for discordant grafting in man. Transplant Proc. 1992;24:559-562.
40. Sandrin M, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Galα1-3Gal epitopes. Proc Natl Acad Sci USA. 1993;90:11391-11395.
41. Collins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of α-galactosyl determinant in hyperacute rejection. J Immunol. 1995;154:5500-5510.
42. Galili U, Repik PK, Anaraki F, Mozdzanowska K, Washko G, Gerhard W. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural anti-Gal antibody. Vaccine. 1996;14:321-328.
43. Galili U, Chen ZC, Manches O, Plumas J, Preisler H. Preparation of autologous leukemia and lymphoma vaccines expressing α-gal epitopes. J Hematother Stem Cell Res. 2001;10:501-511.
44. Galili U, Chen ZC, DeGeest K. Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. Gynecol Oncol. 2003;90:100-108.
45. Thall AD, Maly P, Lowe JB. Oocyte Galα1-3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem. 1995;270:21437-21440.
46. LaTemple DC, Galili U. Adult and neonatal anti-Gal response in knock-out mice for α-galactosyltransferase. Xenotransplantation. 1998;5:191-196.
47. Tanemura M, Ogawa H, Yin DP, Chen ZC, DiSesa VJ, Galili U. Elimination of anti-Gal B cells by α-gal ricin. Transplantation. 2002;73:1859-1868.
48. Unfer RC, Hellrung D, Link Jr CJ. Immunity to the α(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing α(1,3)galactosyltransferase: a novel suicide gene for cancer gene therapy. Cancer Res. 2003;63:987-993.
49. Gorelik E, Duty L, Anaraki F, Galili U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3galactosyltransferase gene transfection. Cancer Res. 1995;55:4168-4173.
50. Gorelik E, Xu F, Henion T, Anaraki F, Galili U. Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(α)1-2- galactose after α1,2-fucosyltransferase cDNA transfection. Cancer Res. 1997;57:332-336.
51. Arca ML, Krauss JC, Strome SE, Cameron MJ, Chang AE. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother. 1996;42:237-245.
52. Galili U, LaTemple DC, Radic MZ. A sensitive assay for measuring α-gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation. 1998;65:1129-1132.
53. Galili U, Anaraki F. galactosyl (Galα1-3Galβ1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate α1,3 galactosyltransferase expressed in E. coli. Glycobiology. 1995;5:775-782.
54. Chen ZC, Tanemura M, Galili U. Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris. Glycobiology. 2001;11:577-586.
55. Deriy L, Chen Zc ZC, Gao GP, Galili U. Expression of α-gal epitopes on HeLa cells transduced with adenovirus containing α1, 3galactosyltransferase cDNA. Glycobiology. 2002;12:135-144.
56. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70:8934-8943.
57. Larsen RD, Rajan VP, Ruff M, Kukowska-Latallo J, Cummings RD, Lowe JB. Isolation of a cDNA encoding murine UDP-galactose: α-D-galactosyl-1,4-N- acetyl-D-glucosamine α1,3 galactosyltransferase: expression cloning by gene transfer. Proc Natl Acad Sci USA. 1989;86:8227-8231.
58. Joziasse DH, Shaper NL, Kim D, Van den Eijnden DH, Shaper JH. Murine α1,3-galactosyltransferase. A single gene locus specifies four isoforms of the enzyme by alternative splicing. J Biol Chem. 1992;267:5534-5541.
59. Wood C, Kabat EA, Murphy LA, Goldstein IJ. Immunochemical studies on combining sites of two isolectins A4 and B4 isolated from Bandeiraea simplicifolia. Arch Bicohem Biophys. 1979;198:1-11.
60. Jager U, Takeuchi Y, Porter C. Induction of complement attack on human cells by Gal(α1,3)Gal xenoantigen expression as a gene therapy approach to cancer. Gene Ther. 1999;6:1073-1083.
61. Yoshimura N, Sawada T, Furusawa M, Fuchinoue S. Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing. Cancer Lett. 2001;164:155-160.
62. Aubert M, Crotte C, Bernard JP, Lombardo D, Sadoulet MO, Mas E. Decrease of human pancreatic cancer cell tumorigenicity by α1,3 galactosyltransferase gene transfer. Int J Cancer. 2003;107:910-918.
63. Link Jr CJ, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: α(1,3) galactosyltransferase gene therapy. Anticancer Res. 1998;18:2301-2308.
64. Kim M, Rao MV, Tweardy DJ, Prakash M, Galili U, Gorelik E. Lectin-induced apoptosis of tumour cells. Glycobiology. 1993;3:447-453.
65. LaTemple DC, Abrams JT, Zhang SU, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knock out mice for α1,3 galactosyltranferase. Cancer Res. 1999;59:3417-3423.
66. Ogawa H, Yin DP, Galili U. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene. Gene Ther. 2004;11:292-301.
67. Dranoff G, Jaffe E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
68. Golumbek PT, Azhari R, Jaffee EM, et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 1993;53:5841-5844.
69. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by in vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997;37:1537-1546.